Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sherif S. Farag, MD, PhD
Indiana University
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Moores Ucsd Cancer Center
La Jolla, California, United States
- Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
Los Angeles, California, United States
- Ucsf Comprehensive Cancer Center
San Francisco, California, United States
- Ccop - Christiana Care Health Services
Newark, Delaware, United States
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, United States
- University of Chicago Cancer Research Center
Chicago, Illinois, United States
- Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, United States
- Dana-Farber/harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
- Siteman Cancer Center at Barnes-Jewish Hospital
St Louis, Missouri, United States
- Unmc Eppley Cancer Center at the University of Nebraska Medical Center
Omaha, Nebraska, United States
- St. Joseph'S Hospital and Medical Center
Paterson, New Jersey, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Don Monti Comprehensive Cancer Center at North Shore University Hospital
Manhasset, New York, United States
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
- Mount Sinai Medical Center
New York, New York, United States
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, United States
- Duke Comprehensive Cancer Center
Durham, North Carolina, United States
- Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
Columbus, Ohio, United States
- Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, United States
- Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, United States
- Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2006
- Primary completion
- 31 Jan 2007
- Completion
- 31 Jan 2007
- Last update posted
- 27 Nov 2019
- Registered enrollment
- 0
- Registry id
- NCT00085449
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.